Gene · 5890
Papers1,861
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
321 to 340 of 1,861
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Roles of homologous recombination in response to ionizing radiation-induced DNA damage. | Int J Radiat Biol | 2023 | 34283012 | PubTator, text mining | PubMed |
| Characteristics of homologous recombination repair pathway genes mutation in ovarian cancers. | Cancer Innov | 2022 | 38089758 | PubTator, text mining | PubMed |
| Sclerosing Perivascular Epithelioid Cell Tumor of the Uterus: A Rare Entity Posing Diagnostic Challenge. | J Midlife Health | 2022 | 37324788 | PubTator, text mining | PubMed |
| Ad hoc Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline BRCA Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair Defects. | Cancer Res Commun | 2022 | 36970052 | PubTator, text mining | PubMed |
| Drug-gene Interaction Screens Coupled to Tumor Data Analyses Identify the Most Clinically Relevant Cancer Vulnerabilities Driving Sensitivity to PARP Inhibition. | Cancer Res Commun | 2022 | 36969741 | PubTator, text mining | PubMed |
| Homologous recombination repair gene mutations in Malaysian prostate cancer patients. | Cell Mol Biol (Noisy-le-grand) | 2022 | 36800845 | PubTator, text mining | PubMed |
| Synthetic lethal interactions of DEAD/H-box helicases as targets for cancer therapy. | Front Oncol | 2022 | 36761420 | PubTator, text mining | PubMed |
| Whole-exome sequencing and bioinformatic analyses revealed differences in gene mutation profiles in papillary thyroid cancer patients with and without benign thyroid goitre background. | Front Endocrinol (Lausanne) | 2022 | 36686473 | PubTator, text mining | PubMed |
| The Role of Alternative Splicing Factors, DDB2-Related Ageing and DNA Damage Repair in the Progression and Prognosis of Stomach Adenocarcinoma Patients. | Genes (Basel) | 2022 | 36672781 | PubTator, text mining | PubMed |
| HPV and radiosensitivity of cervical cancer: a narrative review. | Ann Transl Med | 2022 | 36660629 | PubTator, text mining | PubMed |
| Locally Performed HRD Testing for Ovarian Cancer? Yes, We Can! | Cancers (Basel) | 2022 | 36612041 | PubTator, text mining | PubMed |
| Whole exome sequencing in Chinese mucinous pulmonary adenocarcinoma uncovers specific genetic variations different from lung adenocarcinoma. | Front Oncol | 2022 | 36591517 | PubTator, text mining | PubMed |
| Polygenic Risk Score and Risk Factors for Preeclampsia and Gestational Hypertension. | J Pers Med | 2022 | 36579561 | PubTator, text mining | PubMed |
| Challenges in next generation sequencing of homology recombination repair genomic variants in prostate cancer: A nationwide survey and calibration project in China. | Prostate Int | 2022 | 36570645 | PubTator, text mining | PubMed |
| PROpel trial: Are PARP inhibitors ready to become the first-line treatment for mCRPC? | Indian J Urol | 2022 | 36568449 | PubTator, text mining | PubMed |
| Implementation of multigene panel testing for breast and ovarian cancer in South Africa: A step towards excellence in oncology for the public sector. | Front Oncol | 2022 | 36568162 | PubTator, text mining | PubMed |
| Increased HRD score in cisplatin resistant penile cancer cells. | BMC Cancer | 2022 | 36564761 | PubTator, text mining | PubMed |
| RE(III) 3-Furoate Complexes: Synthesis, Structure, and Corrosion Inhibiting Properties. | Molecules | 2022 | 36557968 | PubTator, text mining | PubMed |
| Molecular-Targeted Therapy for Tumor-Agnostic Mutations in Acute Myeloid Leukemia. | Biomedicines | 2022 | 36551764 | PubTator, text mining | PubMed |
| Mechanisms of Drug Resistance in Ovarian Cancer and Associated Gene Targets. | Cancers (Basel) | 2022 | 36551731 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5890/papers?page=17